Improved biological activity of Gly(2)- and Ser(2)-substituted analogues of glucose-dependent insulinotrophic polypeptide

Victor Gault, Peter Flatt, P Harriott, MH Mooney, CJ Bailey, Finbarr O'Harte

Research output: Contribution to journalArticle

Abstract

The therapeutic potential of glucagon-like peptide-1 (GLP-1) in improving glycaemic control in diabetes has been widely studied, but the potential beneficial effects of glucose-dependent insulinotropic polypeptide (GIP) have until recently been almost overlooked. One of the major problems, however, in exploiting either GIP or GLP-1 as potential therapeutic agents is their short duration of action, due to enzymatic degradation in vivo by dipeptidylpeptidase IV (DPP IV). Therefore, this study examined the plasma stability, biological activity and antidiabetic potential of two novel NH2-terminal Ala(2)-substituted analogues of GIP, containing glycine (Gly) or serine (Ser). Following incubation in plasma, (Ser(2))GIP had a reduced hydrolysis rate compared with native GIP, while (Gly(2))GIP was completely stable. In Chinese hamster lung fibroblasts stably transfected with the human GIP receptor, GIP, (Gly(2))GIP and (Ser(2))GIP stimulated cAMP production with EC50 values of 18.2, 14.9 and 15.0 nM respectively. In the pancreatic BRIN-BD1 beta-cell line, (Gly(2))GIP and (Ser(2))GIP (10(-8) M) evoked significant increases (1.2- and 1.5-fold respectively; P
Original languageEnglish
Pages (from-to)133-141
JournalJournal of Endrocrinology
Volume176
Issue number1
Publication statusPublished - Jan 2003

Fingerprint Dive into the research topics of 'Improved biological activity of Gly(2)- and Ser(2)-substituted analogues of glucose-dependent insulinotrophic polypeptide'. Together they form a unique fingerprint.

Cite this